Allakos Inc

Allakos — Investor Presentation (June 2024)

30 slides from Allakos's investor presentation, Jun 25, 2024

  1. Slide 1: Corporate Presentation June 2024

    Corporate Presentation June 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); estimated lirentelimab closeout,

  3. Slide 3: Allakos Opportunity

    Allakos Opportunity Novel Target Milestones 3Q24 – Report safety, PK, and PD results from the Phase 1 trial of subcutaneous AK006 in healthy volunteers YE24 – Report topline Phase 1 data of AK006 in patients with CSU AK006 (anti-Siglec-6 mAb) selectively inhibits multiple modes of mast cell activati

  4. Slide 4: Mast Cells Are Key Drivers of Inflammatory Disease

    Mast Cells Are Key Drivers of Inflammatory Disease IL-13

  5. Slide 5: Leveraging the Native Inhibitory Function of Siglecs on Mast Cells

    Leveraging the Native Inhibitory Function of Siglecs on Mast Cells Activated State Siglec-Mediated Inhibition Mast cells can be activated by numerous receptors leading to mast cell degranulation and release of histamine, TNFα and other inflammatory mediators Activation of Siglec-6 with an agonistic

  6. Slide 6: AK006 is Engineered for Deep Mast Cell Inhibition

    AK006 is Engineered for Deep Mast Cell Inhibition AK006 is a Siglec-6 mAb that selectively inhibits mast cells and reduces their numbers Engineered for deep mast cell inhibition Reduces mast cells via ADCP in presence of activated macrophages AK006 inhibits multiple mast cell activation pathways inc

  7. Slide 7: Allakos Pipeline

    Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Milestone AK006 (Anti-Siglec-6) Healthy Volunteers & CSU Expected SC results from healthy volunteers in 3Q24; Expected CSU results at YE24 AK068 (Siglec-6/Siglec-8 Bispecific) Inflammatory Diseases Ongoing T Cell Immunomodulatory Recep

  8. Slide 8: Mast Cells Play a Significant Role in Many Diseases

    Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Duodenitis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTESTINAL DISEASES OPHTHA

  9. Slide 9: AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells

    AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells

  10. Slide 10: Siglec-6 Biology and AK006

    Siglec-6 is a more potent inhibitory receptor than Siglec-8 Siglec-6 regulates more cellular processes than Siglec-8: Signal Transduction Transcription Translation Cellular metabolism Degranulation AK006 has two key attributes Long residence time on the cell surface which correlates to increased inh

  11. Slide 11: Siglec-6 and Siglec-8 Differentially Interact with Proteins that Regulate Mast Cell Activity

    Siglec-6 and Siglec-8 Differentially Interact with Proteins that Regulate Mast Cell Activity Gray lines represent direct interaction Cytokine Signaling Protein Processing (Translation) TGFb Signaling Interferon-Related Cytoplasmic Transport Mitochondrial Translocation Ubiquitin Activity (Protein Deg

  12. Slide 12: AK006 Was Designed to Drive Deep Mast Cell Inhibition

    AK006 was Designed to Drive Deep Mast Cell Inhibition AK002 AK006 Mast cell inhibition for AK002 and AK006 requires Fc-Fc𝛾 receptor interaction Binding of AK006 leads to minimal receptor internalization, resulting in greater mast cell inhibition AK006 displays a high residence time on mast cells…

  13. Slide 13: AK006 Displays Greater Mast Cell Inhibition than AK002 in Preclinical Studies

    AK006 Displays Greater Mast Cell Inhibition than AK002 in Preclinical Studies IgE Activation AK006 inhibits IgE-dependent and IgE–independent modes of mast cell activation better than AK002 n=3 human donors SOURCE: Korver, W. et al Allergy 2024; Benet Z, et al. AAAAI 2024 Presentation. KIT Activatio

  14. Slide 14: AK006 Reduces Human Mast Cells via ADCP in Preclinical Studies

    AK006 Reduces Human Mast Cells via Antibody-Dependent Cellular Phagocytosis in Preclinical Studies In addition to mediating broad inhibition, AK006 can reduce mast cell numbers Ex Vivo Human Tissue Mast Cells - IFN𝞬 Activated Macrophages + IFN𝞬 Activated Macrophages Mast Cells in Tissue * p <…

  15. Slide 15: AK006 Inhibits IgE-Mediated Mast Cell Activation Similar to Remibrutinib

    AK006 Inhibits IgE-Mediated Mast Cell Activation Similar to Remibrutinib IgE-Activated Human Tissue Mast Cells AK006 inhibits IgE-mediated mast cell activation Human Mast Cell Activation Assay n=3 human donors SOURCE: Korver W, et al. EAACI 2023 Presentation.

  16. Slide 16: AK006 Protects Against Systemic Anaphylaxis in Humanized Mice

    AK006 Protects Against Systemic Anaphylaxis in Humanized Mice Humanized Model of Anaphylactic Death Systemic Anaphylaxis AK006 inhibits IgE-mediated mast cell activation in vivo Humanized Mouse Model of Anaphylaxis Anaphylactic Death SOURCE: Schanin, J et al. Communications Biology 2022 **** p < 0.0

  17. Slide 17: AK006 Resolves Gastric Inflammation in Oral Food Challenge Model

    AK006 Resolves Gastric Inflammation in Oral Food Challenge Model AK006 shows inhibitory and depleting effects in food challenge model Stomach Mast Cells * p < 0.01, n=6 mice/group Transcriptional Profiling of Stomach Mast Cells Corporate Model of OVA-Induced Allergic Enteritis SOURCE: Benet Z, et al

  18. Slide 18: AK006 in Phase 1 Clinical Study in Healthy Volunteers and CSU

    AK006 in Phase 1 Clinical Study in Healthy Volunteers and Chronic Spontaneous Urticaria

  19. Slide 19: Phase 1 Study Design

    AK006 Phase 1 Study Design Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts in Healthy Volunteers Randomized, double-blind, placebo-controlled Intravenous AK006 SAD: 5, 20, 80, 240, 720 mg MAD: 80, 240, 720 mg monthly Subcutaneous AK006 150 and 720 mg Planned CSU Cohort Randomiz

  20. Slide 20: Phase 1 SAD & MAD Baseline Demographics and Characteristics

    Phase 1 IV SAD & MAD Baseline Demographics and Characteristics Characteristics Single Ascending Dose (IV) Multiple Ascending Dose (IV) Baseline Characteristics AK006 5mg AK006 20mg AK006 80mg AK006 240mg AK006 720mg Placebo AK006 80mg AK006 240mg AK006 720mg Placebo Subjects, n 12 6 6 6 6 12 6 6 6 6

  21. Slide 21: AK006 was Well-Tolerated with a Favorable Safety Profile

    AK006 was Well-Tolerated with a Favorable Safety Profile Single and multiple IV doses of AK006 up to 720 mg were well-tolerated with a favorable safety profile There were no serious adverse events (SAEs) There were no treatment emergent adverse events leading to discontinuation of AK006 There were n

  22. Slide 22: AK006 Shows Linear Exposure with a Half-life of Days at 720mg

    AK006 Shows Linear Exposure with a Half-life of 21 Days at 720mg Days Days Mean (±SD) Serum Concentration (µg/mL) AK006 720 mg AK006 240 mg AK006 80 mg AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments AK006 720 mg AK006 240 mg AK

  23. Slide 23: High Siglec-6 Occupancy is Observed at Low Doses

    High Siglec-6 Occupancy is Observed at Low Doses Siglec-6 receptor occupancy on mast cell cells from skin biopsies was quantified in the Phase 1 study of AK006 Doses of AK006 ≥20mg showed mean Siglec-6 receptor occupancy >90% on skin mast cells at Day 29 The high occupancy levels on skin mast cells

  24. Slide 24: AK006 for Chronic Spontaneous Urticaria

    AK006 for Chronic Spontaneous Urticaria

  25. Slide 25: AK006 May Inhibit Disease Driving Pathways in Urticaria

    AK006 May Inhibit Disease Driving Pathways in Urticaria Activated mast cells drive the pathogenesis of urticaria via release of inflammatory mediators resulting in pruritis, vasodilation, and increased vascular permeability Blocking both IgE activation and IgE-independent mast cell activation could

  26. Slide 26: Chronic Spontaneous Urticaria Opportunity

    Chronic Spontaneous Urticaria Opportunity CSU affects up to 3 million adults in the U.S., with 2 million managed by a specialist (allergist or dermatologist)1,2 Approximately 800k adult CSU patients are eligible for a biologic in the U.S. 1. Maurer M, et al. Allergy. 2011 Mar;66(3):317-30. 2. Allako

  27. Slide 27: Chronic Spontaneous Urticaria Landscape

    Chronic Spontaneous Urticaria Landscape Drug Name MOA UAS7 Response Opportunity Xolair® (omalizumab) Anti-IgE mAb Dose Group1 150 mg 300 mg Placebo Placebo >50% of patients continue to have symptoms Black box for anaphylaxis1 UAS7 -14.4 (-48%) -20.8 (-66%) -8.0 (-26%) -8.0 (-26%) UAS7=0 15% 36% 9% 9

  28. Slide 28: Financial Overview & Key Milestones

    Financial Overview & Key Milestones

  29. Slide 29: Data Catalysts and Expected Milestones

    Data Catalysts and Expected Milestones Q2 2024: Report SAD and MAD safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 IV AK006 trial in healthy volunteers, including data to confirm Siglec-6 receptor occupancy in skin biopsy samples. Q2 2024: Initiate the randomized, do

  30. Slide 30: Balance Sheet and IP Protection

    Cash, Cash Equivalents and Investments in Marketable Securities as of December 31, 2023 $170.8 M – Estimated 2024 cash used in restructuring (lirentelimab closeout, severance and other costs) $30 M – Estimated 2024 cash used in ongoing business operations $55 to $60 M Estimated, Cash, Cash Equivalen

Allakos — Investor Presentation (June 2024) on 6ix